Literature DB >> 21948887

Pathogenic mechanisms of depression in multiple sclerosis.

Joe John Vattakatuchery1, Hugh Rickards, Andrea Eugenio Cavanna.   

Abstract

Patients with multiple sclerosis (MS) have an increased risk of developing depression as compared with healthy subjects and patients with many other chronic neurological conditions. The observation that depressive symptoms can precede the onset of neurological symptoms suggests that depression may be related to early disease-specific processes. Several pathogenic mechanisms have been proposed to explain the etiology of depression in patients with MS. This article reviews the current evidence for the contribution of lesional, autoimmune, iatrogenic, and psychosocial factors. It appears that the etiology of depression is multifactorial and varies in individual patients with MS.

Entities:  

Mesh:

Year:  2011        PMID: 21948887     DOI: 10.1176/jnp.23.3.jnp261

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  17 in total

Review 1.  [Coexistent depressive and anxiety disorders in epilepsy and multiple sclerosis: a challenge to neuropsychiatric practice].

Authors:  Hans-Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2014-05-20

2.  Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN.

Authors:  Antonios Bayas; Katrin Schuh; Monika Baier; Stefan Viktor Vormfelde
Journal:  Ther Adv Neurol Disord       Date:  2016-06-03       Impact factor: 6.570

3.  Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation.

Authors:  Ana Paula Kallaur; Josiane Lopes; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Edna Maria Vissoci Reiche; Elaine Regina Delicato de Almeida; Helena Kaminami Morimoto; Wildea Lice Carvalho Jennings de Pereira; Daniele Frizon Alfieri; Sueli Donizete Borelli; Domacio Ramon Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-09-24       Impact factor: 5.590

4.  Depression and Anxiety are Common in Acute HIV Infection and Associate with Plasma Immune Activation.

Authors:  Joanna Hellmuth; Donn Colby; Victor Valcour; Duanghathai Suttichom; Serena Spudich; Jintanat Ananworanich; Peeriya Prueksakaew; Napapon Sailasuta; Isabel Allen; Linda L Jagodzinski; Bonnie Slike; Derek Ochi; Robert Paul
Journal:  AIDS Behav       Date:  2017-11

Review 5.  Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder.

Authors:  Aaron P Turner; Kevin N Alschuler; Abbey J Hughes; Meghan Beier; Jodie K Haselkorn; Alicia P Sloan; Dawn M Ehde
Journal:  Curr Neurol Neurosci Rep       Date:  2016-12       Impact factor: 5.081

Review 6.  Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment.

Authors:  Claudio Solaro; Giulia Gamberini; Fabio Giuseppe Masuccio
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

Review 7.  Psychiatric manifestations in cerebrotendinous xanthomatosis.

Authors:  M J Fraidakis
Journal:  Transl Psychiatry       Date:  2013-09-03       Impact factor: 6.222

Review 8.  Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.

Authors:  Robert Hoepner; Simon Faissner; Anke Salmen; Ralf Gold; Andrew Chan
Journal:  J Cent Nerv Syst Dis       Date:  2014-04-28

9.  Lifestyle factors, demographics and medications associated with depression risk in an international sample of people with multiple sclerosis.

Authors:  Keryn L Taylor; Emily J Hadgkiss; George A Jelinek; Tracey J Weiland; Naresh G Pereira; Claudia H Marck; Dania M van der Meer
Journal:  BMC Psychiatry       Date:  2014-12-03       Impact factor: 3.630

10.  The risk of developing depression when suffering from neurological diseases.

Authors:  C Thielscher; S Thielscher; K Kostev
Journal:  Ger Med Sci       Date:  2013-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.